Category: Glenmark
-
Bayer Xarelto cases: Denmark becomes interesting patent PI jurisdiction after first Supreme Court clarification of strong validity presumption
The top Danish court also spoke out on the impact of redundant patent claim elements.
-
Post-judgment cleanup orders in UK pharma cases: no disgorgement of Bayer profits; Teva, Glenmark, Generics (UK) recover two thirds of costs
AstraZeneca must reimburse two thirds of the costs of an unsuccessful case Teva, Glenmark and Generics (UK). Separately, Bayer does not have to disgorge profits to Sandoz.